Sun Pharmaceutical Industries shares fall 2.01% in today's trading session

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Sun Pharmaceutical Industries experienced a decline of 2.01% to trade at Rs 1,568.20 on Thursday. The stock is a constituent of the Nifty 50 index.

Quarterly Financial Highlights:

The consolidated financial performance of Sun Pharmaceutical Industries reveals the following trends:

Revenue: The company's revenue has shown a consistent increase over the past five quarters. The revenue for the quarter-ending June 2025 stood at Rs 13,851.40 Crore, compared to Rs 12,652.75 Crore for the quarter-ending June 2024.

Net Profit: The net profit saw a slight decrease in the latest quarter. For the quarter-ending June 2025, the net profit was Rs 2,302.62 Crore, compared to Rs 2,871.25 Crore for the quarter-ending June 2024.

EPS: The earnings per share (EPS) also experienced a decrease. The EPS for the quarter-ending June 2025 was Rs 9.50, compared to Rs 11.80 for the quarter-ending June 2024.

The consolidated annual financial performance shows:

Revenue: There has been a steady increase in revenue over the years. The revenue for the year-ending March 2025 was Rs 52,578.44 Crore, an 8.42 percent increase compared to Rs 48,496.85 Crore for the year-ending March 2024.

Net Profit: The net profit has also increased. The net profit for the year-ending March 2025 was Rs 10,980.10 Crore, a 13.80 percent increase compared to Rs 9,648.44 Crore for the year-ending March 2024.

EPS: The earnings per share (EPS) have risen consistently. The EPS for the year-ending March 2025 was Rs 45.60, compared to Rs 39.90 for the year-ending March 2024.

BVPS: The book value per share (BVPS) has also increased. The BVPS for the year-ending March 2025 was Rs 301.00, compared to Rs 265.36 for the year-ending March 2024.

ROE: The return on equity (ROE) remained stable. The ROE for the year-ending March 2025 was 15.13%, the same as the year-ending March 2024.

Debt to Equity: The debt-to-equity ratio has decreased. The debt-to-equity ratio for the year-ending March 2025 was 0.03, compared to 0.04 for the year-ending March 2024.

The company has announced dividends. A final dividend of Rs 5.50 per share (550%) was announced on May 22, 2025, with an effective date of July 7, 2025. An interim dividend of Rs 10.50 per share (1050%) was announced on January 16, 2025, with an effective date of February 6, 2025.

The company has issued bonus shares. On May 28, 2013, the company announced a bonus ratio of 1:1, with a record date of July 30, 2013, and an ex-bonus date of July 29, 2013. On April 21, 2004, the company announced a bonus ratio of 1:1, with a record date of May 29, 2004, and an ex-bonus date of May 27, 2004. On February 9, 2000, the company announced a bonus ratio of 2:1, with a record date of March 23, 2000, and an ex-bonus date of March 6, 2000.

The company has split its shares. On September 24, 2010, the company announced a stock split, changing the face value from Rs 5 to Rs 1, with an ex-split date of November 25, 2010, and a record date of November 26, 2010. On October 28, 2002, the company announced a stock split, changing the face value from Rs 10 to Rs 5, with an ex-split date of January 13, 2003, and a record date of January 21, 2003.

Moneycontrol analysis as of August 21, 2025, indicates a bearish sentiment on the stock.

In summary, Sun Pharmaceutical Industries' stock experienced a decline today, while the company has demonstrated steady growth in revenue and net profit over the past few years, along with recent corporate actions including dividend announcements, bonus issues, and stock splits.